Sarwat T. Khan

525 Boulevard Cartier Ouest
Laval, QC H7V3S8, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein.

A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein.

Journal: Cell reports

Published: September 30, 2024

Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis.

Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis.

Journal: The Lancet. Microbe

Published: July 28, 2023

Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.

Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.

Journal: Frontiers in immunology

Published: August 30, 2022

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.

Journal: Frontiers in immunology

Published: August 27, 2022

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.

Journal: Nature communications

Published: November 11, 2021

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.

Journal: EClinicalMedicine

Published: October 13, 2021

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.

Journal: medRxiv : the preprint server for health sciences

Published: September 28, 2021

Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.

Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: July 30, 2021

Perioperative arginine prevents metastases by accelerating natural killer cell recovery after surgery.

Perioperative arginine prevents metastases by accelerating natural killer cell recovery after surgery.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: June 02, 2021

Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis.

Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis.

Journal: Hematological oncology

Published: March 20, 2021

Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews.

Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews.

Journal: BMJ open

Published: June 11, 2020

Killers 2.0: NK cell therapies at the forefront of cancer control.

Killers 2.0: NK cell therapies at the forefront of cancer control.

Journal: The Journal of clinical investigation

Published: September 04, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026